Merck Manual

Please confirm that you are a health care professional

Loading

Amniotic Fluid Embolism

By

Julie S. Moldenhauer

, MD, Children's Hospital of Philadelphia

Last full review/revision Jan 2020| Content last modified Jan 2020
Click here for Patient Education

Amniotic fluid embolism is a clinical syndrome of hypoxia, hypotension, and coagulopathy that results from entry of fetal antigens into the maternal circulation.

Amniotic fluid embolism is a rare obstetric emergency, estimated to occur in 2 to 6/100,000 pregnancies. It usually occurs during late pregnancy but may occur during termination of a 1st- or 2nd-trimester pregnancy.

Although mortality estimates vary widely (from about 20 to 90%), the syndrome clearly poses a significant risk, and of women who die suddenly during labor, amniotic fluid embolism is one of the most likely causes (1). Survival depends on early recognition and immediate institution of treatment.

General reference

  • 1. Clark SL: Amniotic fluid embolism. Obstet Gynecol 123:337-348, 2014. doi: 10.1097/AOG.0000000000000107.

Pathophysiology

The long-standing term amniotic fluid "embolism" implies a primarily mechanical, obstructive disorder, as occurs in thromboembolism or air embolism. However, because amniotic fluid is completely soluble in blood, it cannot cause obstruction. Furthermore, the minor amounts of fetal cells and tissue debris that may accompany the amniotic fluid into the maternal circulation are too small to mechanically obstruct enough of the pulmonary vascular tree to cause the marked hemodynamic changes that occur in this syndrome.

Instead, it is currently thought that exposure to fetal antigens during delivery activates proinflammatory mediators, which trigger an overwhelming inflammatory cascade and release of vasoactive substances (eg, norepinephrine) similar to the systemic inflammatory response syndrome (SIRS) that occurs in sepsis and septic shock.

The inflammatory response causes organ damage, particularly to the lungs and heart, and triggers the coagulation cascade, resulting in disseminated intravascular coagulation (DIC). The resulting maternal hypoxia and hypotension have profound adverse effects on the fetus.

Because maternal exposure to fetal antigens is likely fairly common during labor and delivery, it is not clear why only a few women develop amniotic fluid embolism. It is thought that different fetal antigens in varying amounts probably interact with unknown maternal susceptibility factors.

Risk factors

Many factors are associated with increased risk of amniotic fluid embolism, but evidence is inconsistent. As with exposure to fetal antigens, many of the risk factors are commonplace or at least much more likely than amniotic fluid embolism, and there is no good pathophysiologic understanding of why only a few women with risk factors develop the syndrome. Nonetheless, risk is generally thought to be increased by the following:

Symptoms and Signs

Amniotic fluid embolism usually manifests during and shortly after labor and delivery. The first sign may be sudden cardiac arrest. Other patients suddenly develop dyspnea and have tachycardia, tachypnea, and hypotension. Respiratory failure, with significant cyanosis, hypoxia and pulmonary crackles, often quickly follows.

Coagulopathy manifests as bleeding from the uterus and/or sites of incisions and venipuncture.

Uterine hypoperfusion causes uterine atony and fetal distress.

Diagnosis

  • Clinical evaluation

  • Exclusion of other causes

Diagnosis of amniotic fluid embolism is suspected when the classic triad develops during labor or immediately after delivery:

  • Sudden hypoxia

  • Hypotension

  • Coagulopathy

Diagnosis is clinical and by excluding other causes of the following:

Autopsy may detect fetal squamous cells and hair in the pulmonary circulation, but this finding does not confirm the diagnosis. Fetal cells are sometimes detected in patients who do not have the amniotic fluid embolism.

Treatment

  • Supportive care

Treatment of amniotic fluid embolism is supportive. It includes transfusion of red blood cells (as needed to replace lost blood) and fresh frozen plasma and clotting factors (as needed to reverse the coagulopathy) plus ventilatory and circulatory support, with inotropic drugs as needed. Recombinant factor VIIa should not be used routinely but may be given to women who continue to bleed heavily despite use of other clotting factors.

Immediate operative delivery can improve maternal outcome and can be critical for survival of a fetus that is a viable gestational age.

Key Points

  • Amniotic fluid embolism typically occurs during labor and delivery and causes a triad of hypoxia, hypotension, and coagulopathy.

  • The disorder is not a mechanical embolic phenomenon but is probably a biochemical response in which exposure to fetal antigens triggers an overwhelming inflammatory response in the mother.

  • Mortality is high, and patients require immediate aggressive respiratory and hemodynamic support and replacement of clotting factors.

  • Immediate delivery is necessary for survival of a fetus that is a viable gestational age; it can also improve maternal outcome.

Drugs Mentioned In This Article

Drug Name Select Trade
LEVOPHED
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
The Position of the Baby
Video
The Position of the Baby
3D Models
View All
Vaginal Birth
3D Model
Vaginal Birth

SOCIAL MEDIA

TOP